Browse by author
Lookup NU author(s): Professor Alison Yarnall, Dr Rachael LawsonORCiD, Dr Gordon Duncan, Dr Tien Kheng Khoo, Professor David BurnORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Background The immune system is a promising therapeutic target for disease modification in Parkinson's disease (PD), but appropriate immune-related biomarkers must be identified to allow patient stratification for trials and tracking of therapeutic effects. The objective of this study was to investigate whether immune markers in peripheral blood are candidate prognostic biomarkers through determining their relationship with disease progression in PD. Methods Serum samples were collected in incident PD cases and age-matched controls. Subjects were clinically evaluated at baseline and 18 and 36 months. Ten cytokines and C-reactive protein were measured, with data reduction using principal-component analysis, and relationships between component scores and motor (MDS Unified Parkinson's Disease Rating Scale — part 3) and cognitive (Mini Mental State Examination [MMSE]) measures of disease severity/progression were investigated. Results TNF-α, IL1-β, IL-2, and IL-10 were higher in PD (n = 230) than in controls (n = 93), P ≤ 0.001). Principal-component analysis of log-transformed data resulted in a 3-component solution explaining 51% of the variance. Higher "proinflammatory" and lower "anti-inflammatory" component scores were associated with more rapid motor progression over 36 months (P<0.05), and higher "proinflammatory" component scores were associated with lower MMSE at all times (P<0.05). Multiple linear regression analysis with adjustment for covariates confirmed "anti-inflammatory" component score was the strongest predictor of slower motor progression (β = −0.22, P=0.002), whereas proinflammatory cytokines were associated with lower baseline MMSE (β = −0.175, P=0.007). Conclusions Serum immune marker profile is predictive of disease progression in PD and hence a potential prognostic biomarker. However, interventional trials are needed to clarify whether peripheral immune changes causally contribute to the progression of PD.
Author(s): Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, Cummings GA, Duncan GW, Khoo TK, Burn DJ, Barker RA, on behalf of the ICICLE-PD study group
Publication type: Article
Publication status: Published
Journal: Movement Disorders
Year: 2016
Volume: 31
Issue: 7
Pages: 995-1003
Print publication date: 01/07/2016
Online publication date: 21/03/2016
Acceptance date: 06/01/2016
Date deposited: 03/05/2016
ISSN (print): 0885-3185
ISSN (electronic): 1531-8257
Publisher: John Wiley & Sons, Inc.
URL: http://dx.doi.org/10.1002/mds.26563
DOI: 10.1002/mds.26563
Altmetrics provided by Altmetric
